Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide
BMJ Case Reports
Pomalidomide is an immunomodulatory drug used for relapsed and refractory multiple myeloma (RRMM). Hypothyroidism is an uncommon side effect of pomalidomide. We present a 70-year-old male patient with RRMM on daratumumab, pomalidomide and dexamethasone, who presented with 2 weeks of fatigue. Laboratory values showed sodium of 120 mEq/L, plasma osmolarity of 256 mOsm/kg, urine osmolarity of 648 mOsm/kg and urine sodium of 93 mEq/L. Adrenocorticotropic hormone (ACTH) stimulation test was within normal limits. Thyroid-stimulating hormone (TSH) was 88.6 IU/mL (0.380-4.700 IU/mL), total triiodothyronine (TT3)/mL (0.8-2 ng/mL), free thyroxine (fT4) 0.10 ng/dL (0.93-1.70 ng/dL) and free triiodothyronine (fT3)
Qureshi A, Rhee JH. Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide. BMJ Case Rep. 2021 Mar 2;14(3):e240168. doi: 10.1136/bcr-2020-240168. PMID: 33653858; PMCID: PMC7929826.